Table 1. (a) Summary of in vitro therapy data; (b) Interaction of Oncovexgalv/CD and mitomycin C on three TCC cell line; (c) Interaction of Oncovexgalv/CD and cisplatin on three TCC cell line; (d) Interaction of Oncovexgalv/CD and gemcitabine on three TCC cell line.
| Cell type | Hystological type | HSV-1 CPE efficacy | Fusion efficacy | Prodrug efficacy |
|---|---|---|---|---|
| (a) | ||||
| EJ | TCC | + | + | + |
| T24 | TCC | + | + | − |
| RT112 | TCC | + | − | + |
| VMCUB-I | TCC | + | + | − |
| TCCSUP-G | TCC | + | − | + |
| 5637 | TCC | + | + | + |
| KU19-19 | TCC | + | − | + |
| Cell line | ED50 | ED70 | ED95 |
|---|---|---|---|
| (b) | |||
| EJ | 0.77±0.05 | 0.80±0.04 | 0.86±0.04 |
| T24 | 0.65±0.07 | 0.61±0.04 | 0.73±0.07 |
| KU19-19 | 0.78±0.01 | 0.58±0.06 | 0.57±0.08 |
| (c) | |||
| EJ | 2.6±0.12 | 2.29±0.01 | 2.11±0.01 |
| T24 | 2.34±0.02 | 2.03±0.24 | 1.8±0.4 |
| TCCSUPG | 1.73±0.16 | 1.28±0.13 | 1.09±0.21 |
| (d) | |||
| EJ | 2.92±0.38 | 2.08±0.24 | 1.53±0.24 |
| T24 | 1.54±0.43 | 0.89±0.22 | 0.59±0.12 |
| TCCSUPG | 1.42±0.13 | 1.18±0.47 | 1.18±0.78 |
Abbreviations: CPE=cytopathic effect; HSV=herpes simplex virus; TCC=transitional cell cancer.
The effect of the combination of OncovexGALV/CD and chemotherapy on cell proliferation was assessed by calculating combination index (CI) values using CalcuSyn software (Biosoft). Derived from the median-effect principle of Chou and Talalay, the CI provides a quantitative measure of the degree of interaction between two or more agents. A CI of 1 denotes an additive interaction, >1 antagonism, and <1 synergy. Experiments were done as described for the in vitro survival assay using 4, 2, 1, 0.5, and 0.25 times the calculated ED50 of each agent in a constant ratio checkerboard design.